• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

    11/14/24 3:53:30 PM ET
    $ATNF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNF alert in real time by email
    SC 13G/A 1 armistice-atnf093024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    180 Life Sciences Corp.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    68236V302

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  68236V302
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    53,935
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    53,935
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    53,935
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.99%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  68236V302
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    53,935
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    53,935
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    53,935
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.99%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 68236V302
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    180 Life Sciences Corp.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    3000 El Camino Real

    Bldg. 4, Suite 200

    Palo Alto, CA 94306

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, par value $0.0001 per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    68236V302

     

    CUSIP No.  68236V302
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 68236V302
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of September 30, 2024:

    Armistice Capital, LLC - 53,935

    Steven Boyd - 53,935   

    (b) Percent of Class as of September 30, 2024:

    Armistice Capital, LLC - 4.99%

    Steven Boyd - 4.99% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 53,935

    Steven Boyd - 53,935  

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 53,935

    Steven Boyd - 53,935

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 68236V302
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 68236V302
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $ATNF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATNF

    DatePrice TargetRatingAnalyst
    9/15/2021$11.00Buy
    Maxim Group
    More analyst ratings

    $ATNF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 180 Life Sciences Corp.

      SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)

      11/14/24 3:53:30 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 180 Life Sciences Corp.

      SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

      10/18/24 5:00:02 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 180 Life Sciences Corp.

      SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)

      2/14/24 3:27:19 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Jordan Blair acquired 1,318,000 shares (SEC Form 4)

      4 - 180 Life Sciences Corp. (0001690080) (Issuer)

      4/30/25 5:57:06 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Elray Resources, Inc. converted options into 1,318,000 shares (SEC Form 4)

      4 - 180 Life Sciences Corp. (0001690080) (Issuer)

      4/11/25 6:05:04 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Jordan Blair acquired 200,000 shares (SEC Form 4)

      4 - 180 Life Sciences Corp. (0001690080) (Issuer)

      4/2/25 4:59:04 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Woody James N. bought $4,700 worth of shares (25,000 units at $0.19), increasing direct ownership by 60% to 66,888 units (SEC Form 4)

      4 - 180 Life Sciences Corp. (0001690080) (Issuer)

      12/18/23 4:15:16 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on 180 Life Sciences Corp. with a new price target

      Maxim Group initiated coverage of 180 Life Sciences Corp. with a rating of Buy and set a new price target of $11.00

      9/15/21 7:48:59 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    SEC Filings

    See more
    • SEC Form S-3 filed by 180 Life Sciences Corp.

      S-3 - 180 Life Sciences Corp. (0001690080) (Filer)

      5/9/25 4:15:31 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by 180 Life Sciences Corp.

      10-K/A - 180 Life Sciences Corp. (0001690080) (Filer)

      5/8/25 4:20:24 PM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - 180 Life Sciences Corp. (0001690080) (Filer)

      5/1/25 9:18:16 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Financials

    Live finance-specific insights

    See more
    • 180 Life Sciences Corp. - Corporate Updates

      Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve

      10/3/24 8:30:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Leadership Updates

    Live Leadership Updates

    See more
    • 180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

      PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f

      12/12/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

      PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his

      12/4/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors

      PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately. Mr. Goodman brings over a decade of expertise in the software-as-a-service (SaaS) and iGaming industries, along with more than seven years of experience in executive leadership roles. Mr. Goodman's distinguished career includes contributions to several high-growth companies, successful IPOs, and extensive work in the Asia Pacific and Japan markets.Currently, Mr. Goodman serves as Sales Director for Asia Pacific and Japan at Docker, Inc., a position he has held since January 2024. Doc

      10/29/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules

      PALO ALTO, CA / ACCESSWIRE / December 27, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct offering priced at market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 1,200,000 shares of common stock. The combined effective offering price for each share of common stock and accompanying wa

      12/27/24 9:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

      PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce that it has regained compliance with Nasdaq Listing Rule 5605(c)(2), which requires Nasdaq listed companies to maintain an audit committee consisting of three independent directors. This development follows the recent appointment of Mr. Stephen Shoemaker as an independent director of the Company and as a member of the Company's audit committee. With this appointment, 180 is now in full compliance with all Nasdaq continued listing requirements and has remedied all previously announced deficiencies.Mr. Blair Jordan, Interim CEO of the Company, stated, "This brings 180 into f

      12/12/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors

      PALO ALTO, CA / ACCESSWIRE / December 4, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF), a biotechnology company that is currently refocusing its business on the international entertainment and iGaming sector, today announced the appointment of Stephen Shoemaker to its Board of Directors, effective December 3, 2024.Mr. Shoemaker brings to 180 a wealth of experience as a seasoned senior executive and board member with a diverse background spanning finance, operations management, capital raising, and strategic planning. With over $2 billion in capital raised during his tenure in both CEO and CFO roles across four companies, Mr. Shoemaker has consistently demonstrated his

      12/4/24 8:00:00 AM ET
      $ATNF
      Biotechnology: Pharmaceutical Preparations
      Health Care